BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21130491)

  • 21. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
    Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
    Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Genetic analysis of endometriosis and ovarian cancer].
    Obata K; Hoshiai H
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():217-20. PubMed ID: 11235170
    [No Abstract]   [Full Text] [Related]  

  • 23. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations.
    Munksgaard PS; Blaakaer J
    Gynecol Oncol; 2012 Jan; 124(1):164-9. PubMed ID: 22032835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allelic loss studies do not provide evidence for the "endometriosis-as-tumor" theory.
    Prowse AH; Fakis G; Manek S; Churchman M; Edwards S; Rowan A; Koninckx P; Kennedy S; Tomlinson IP
    Fertil Steril; 2005 Apr; 83 Suppl 1():1134-43. PubMed ID: 15831286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The malignant potential of ovarian atypical endometriosis].
    Guo L; Liu T; Lang J
    Zhonghua Bing Li Xue Za Zhi; 2001 Jun; 30(3):169-72. PubMed ID: 11866970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study.
    Mhawech P; Kinkel K; Vlastos G; Pelte MF
    Int J Gynecol Pathol; 2002 Oct; 21(4):401-6. PubMed ID: 12352189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis.
    Kobayashi H; Yamada Y; Kawahara N; Ogawa K; Yoshimoto C
    Oncol Rep; 2019 Mar; 41(3):1729-1738. PubMed ID: 30592289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.
    Yamamoto S; Tsuda H; Suzuki K; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2009 Sep; 455(3):261-70. PubMed ID: 19655165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability.
    Fujii H; Matsumoto T; Yoshida M; Furugen Y; Takagaki T; Iwabuchi K; Nakata Y; Takagi Y; Moriya T; Ohtsuji N; Ohtsuji M; Hirose S; Shirai T
    Hum Pathol; 2002 Apr; 33(4):421-8. PubMed ID: 12055677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneous distribution of LOH (loss of heterozygosity) and tumor progression.
    Watanabe T; Matsuda K; Ishihara S
    Gynecol Oncol; 2011 Jun; 121(3):640; author reply 640-1. PubMed ID: 21316748
    [No Abstract]   [Full Text] [Related]  

  • 31. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.
    Ho CM; Lin MC; Huang SH; Huang CJ; Lai HC; Chien TY; Chang SF
    Gynecol Oncol; 2009 Feb; 112(2):307-13. PubMed ID: 19007975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
    Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
    Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
    Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
    Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endometriosis-associated Ovarian Cancers.
    Anglesio MS; Yong PJ
    Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management.
    Mandai M; Yamaguchi K; Matsumura N; Baba T; Konishi I
    Int J Clin Oncol; 2009 Oct; 14(5):383-91. PubMed ID: 19856044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study.
    Govatati S; Kodati VL; Deenadayal M; Chakravarty B; Shivaji S; Bhanoori M
    Hum Reprod; 2014 Feb; 29(2):324-36. PubMed ID: 24154570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.
    Linder A; Westbom-Fremer S; Mateoiu C; Olsson Widjaja A; Österlund T; Veerla S; Ståhlberg A; Ulfenborg B; Hedenfalk I; Sundfeldt K
    Hum Reprod; 2024 May; 39(5):1141-1154. PubMed ID: 38459814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic analysis of benign ovarian tumors.
    Thomas NA; Neville PJ; Baxter SW; Campbell IG
    Int J Cancer; 2003 Jul; 105(4):499-505. PubMed ID: 12712441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
    Jongsma AP; Piek JM; Zweemer RP; Verheijen RH; Klein Gebbinck JW; van Kamp GJ; Jacobs IJ; Shaw P; van Diest PJ; Kenemans P
    Mol Pathol; 2002 Oct; 55(5):305-9. PubMed ID: 12354934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis.
    Martini M; Ciccarone M; Garganese G; Maggiore C; Evangelista A; Rahimi S; Zannoni G; Vittori G; Larocca LM
    Int J Cancer; 2002 Dec; 102(4):398-406. PubMed ID: 12402310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.